Ionis Pharmaceuticals Inc [IONS] stock is trading at $73.26, up 2.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The IONS shares have gain 5.35% over the last week, with a monthly amount glided 0.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on October 08, 2025, when JP Morgan upgraded its rating to an Overweight but kept the price target unchanged to $80 for it. Previously, Goldman upgraded its rating to Neutral on September 26, 2025, and kept the price target unchanged to $65. On September 03, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $70 on the stock. Morgan Stanley upgraded its rating to an Overweight but stick to its price target of $62 on July 31, 2025. Barclays upgraded its rating to an Overweight but $57 remained the price target by the analyst firm on July 01, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on April 07, 2025, and assigned it a price target of $45. In a note dated March 31, 2025, Redburn Atlantic initiated a Neutral rating and provided a target price of $39 on this stock.
Ionis Pharmaceuticals Inc [IONS] stock has fluctuated between $23.95 and $76.78 over the past year. Currently, Wall Street analysts expect the stock to reach $83.85 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $73.26 at the most recent close of the market. An investor can expect a potential return of 14.46% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Ionis Pharmaceuticals Inc [NASDAQ:IONS] reported sales of 967.38M for the trailing twelve months, which represents a growth of 17.12%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.29%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.44 and Total Capital is -0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 71.16 points at the first support level, and at 69.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 74.89, and for the 2nd resistance point, it is at 76.52.
Ratios To Look Out For
For context, Ionis Pharmaceuticals Inc’s Current Ratio is 2.79. On the other hand, the Quick Ratio is 2.78, and the Cash Ratio is 0.37. Considering the valuation of this stock, the price to sales ratio is 12.27, the price to book ratio is 19.10.
Transactions by insiders
Recent insider trading involved Birchler Brian, EVP, Corp and Development Ops, that happened on Nov 06 ’25 when 8000.0 shares were sold. EVP, Chief Development Officer, Geary Richard S completed a deal on Nov 06 ’25 to sell 33038.0 shares. Meanwhile, EVP, Chief Development Officer Geary Richard S sold 1601.0 shares on Nov 05 ’25.
